###### Strengths and limitations of this study

-   The strength of our investigation lies in its large sample size, its 4-year follow-up period and its standardised methodology.

-   The second strength is that it has previously been used to investigate adverse drug reaction (ADR)-related hospital admissions in Spain and elsewhere.

-   A limitation of this study is that the possibility that ADR-related hospitalisations also include cases in which the ADR occurred during admission.

Introduction {#s1}
============

Adverse drug reactions (ADRs) are a major health problem owing to their impact on morbidity and mortality. The WHO has defined an ADR as 'any response to a drug which is noxious, unintended and occurs at doses normally used for prophylaxis, diagnosis or therapy of disease, or for modification of physiological function.[@R1] Investigators have performed numerous studies to estimate the incidence of ADRs and have found that between 1.3% and 11.1% of all hospital admissions are due to ADRs.[@R2] The importance of ADRs was highlighted by the fact that since Lazarou *et al*[@R8] concluded that the incidence of fatal ADRs in US hospitals was extremely high (0.31% of all hospitalisations in the late 1990s), other authors have found that hospital mortality resulting from ADRs ranges from 4.3% to 10.2%.[@R5] [@R9]

Research on ADRs also attempts to identify which drugs are most commonly associated with the onset of reactions. Anticoagulants are frequently involved in ADRs requiring hospitalisation.[@R11] This circumstance is reflected in several studies, such as that carried out in the Netherlands by Ruiter *et al*[@R2] among individuals aged ≥55 years, which showed that almost 23% of hospital admissions for ADRs were associated with anticoagulants, and that carried out on elderly patients in France, showed that 25.8% of hospitalisations for ADRs involved anticoagulants.[@R11] Anticoagulants have marked innate toxicity, and oral anticoagulants in particular require close monitoring to ensure safe use. The vitamin K antagonists (VKAs) like warfarin are highly effective in treating and preventing thrombosis, but despite its prolific use, these anticoagulants have several disadvantages. These include a narrow therapeutic index, delayed onset and offset of effect, multiple drug interactions, and requirements for monitoring and high-quality dose management.[@R13] In addition, anticoagulants are often used in elderly persons[@R14] and patients with heart problems,[@R17] who are more susceptible to ADRs.

The objectives of this study are to describe and analyse hospitalisations for ADRs involving anticoagulants based on data from a national hospital discharge database over a 4-year period. We also analyse the progress of the reactions over time, the factors associated with ADRs, and in-hospital outcomes such as in-hospital mortality (IHM) and length of hospital stay.

Methods {#s2}
=======

Definition {#s2a}
----------

According to Spanish legislation, ADRs are noxious and unintended response to drugs. They are considered serious when they are lethal or can be life threatening, are the cause of a defect or congenital malformation, can cause significant or lasting disability or can cause or prolong hospitalisation.

Setting {#s2b}
-------

We performed a retrospective, descriptive, epidemiological study using the Spanish National Hospital Discharge Database (Conjunto Mínimo Básico de Datos, CMBD), which is managed by the Spanish Ministry of Health, Social Services and Equality. The database compiles all public and private hospital data, thus enabling it to cover more than 95% of hospital discharges.[@R19] The CMBD includes patient variables (sex, date of birth), admission date, discharge date, up to 14 discharge diagnoses, and up to 20 procedures performed during the hospital stay. The characteristics of all hospital admissions are registered by medical doctors on the basis of hospital discharge letters and coded by professional coding clerks. The Spanish Ministry of Health, Social Services and Equality sets standards for recordkeeping and performs periodic audits.[@R20] Data collected between 1 January 2010 and 31 December 2013 were analysed. Disease and procedure criteria were defined according to the International Classification of Diseases-Ninth Revision, Clinical Modification (ICD-9-CM),[@R21] which is used in the Spanish CMBD.

We selected CMBD data corresponding to hospital discharges with a diagnosis of ADRs to anticoagulants (ICD-9-CM code E934.2 (coumarin, phenindione, heparin, prothrombin synthesis inhibitors and warfarin)) in any diagnostic field during the study period. Other adverse events (eg, accidents, suicides, accidental overdose and dosing errors) were excluded. The median length of hospital stay and IHM were also estimated for each year studied.

Clinical characteristics included information on overall comorbidity at the time of diagnosis, which was assessed using the Charlson comorbidity index (CCI). The index includes 17 categories of comorbid disease, the scores of which are added to obtain an overall score for each patient.[@R22]

Data analysis {#s2c}
-------------

A descriptive statistical analysis was performed. Depending on their type and distribution, variables were described using percentages, mean with SD and median with IQR. Bivariate analyses of the changes in variables according to year were based on Poisson regression (relative change for incidence by year of discharge), Pearson\'s χ^2^ test (percentages), analysis of variance (means), and the Kruskal-Wallis test (medians). Interactions have been checked according to sex. No sex interaction was found.

We calculated the annual age-specific incidence by dividing the number of cases per year per age group by the corresponding number of people in that population group using data from the National Institute of Statistics reported on 31 December each year.[@R23] We also assessed the number of ADRs to anticoagulants among hospitalised patients and expressed this as a percentage of all hospital admissions in Spain between 2010 and 2013. In addition, we assessed the number of ADRs to anticoagulants among hospitalised patients with respect to the total number of prescriptions for this drug group in Spain between 2010 and 2013. Data on dispensed medical products were obtained from the *National Health Prescription Register* of the *Spanish Ministry of Health, Social Services and Equality.*[@R24] Data from this database were selected at the pharmacological subgroup level B01A code (excluding B01AE and B01AF codes), according to the Anatomical Therapeutic Chemical (ATC) classification system. All data were grouped, thus preventing identification of individual patients.

In order to test the time trend for IHM, logistic regression analyses were performed with mortality as a binary outcome using year of discharge, sex, age and CCI as independent variables. The estimates were expressed as ORs and their 95% CI.

Statistical analyses were performed using Stata V.14.0 (Stata Corp LP, College Station, Texas, USA). Statistical significance was set at p\<0.05 (two-tailed).

Ethical aspects {#s2d}
---------------

Data confidentiality was maintained at all times according to Spanish legislation. Patient identifiers were deleted before the database was provided to the authors in order to maintain patient anonymity. It is not possible to identify patients at the individual level in this article or in the database. Given the anonymous and mandatory nature of the data set, it was not necessary to obtain informed consent.

Results {#s3}
=======

During the 4-year study period, 50 042 individuals were hospitalised with an ADR to an anticoagulant as their primary or secondary diagnosis (6.38% of all ADR-related admissions (50 042/784 635)). [Figure 1](#BMJOPEN2016013224F1){ref-type="fig"} shows the total number of hospitalisations associated with ADRs to anticoagulants during the study period, taking into account the corresponding number of people in that population group, all hospital admissions in Spain between 2010 and 2013, and total number of prescriptions dispensed during this period. Irrespective of the numerator used, an increase in the incidence of hospitalisations with ADRs to anticoagulants can be observed.

![ADRs to anticoagulant in Spain during the period 2010--2013. National Hospital Discharge Database (CMBD). \*Number of prescriptions dispensed BO1A ATC code (except B01AE and B01AF): 39 118 749 (year 2010); 39 899 992 (year 2011); 38 674 897 (year 2012) and 37 877 714 (year 2013). ADR, adverse drug reaction; ATC, Anatomical Therapeutic Chemical; CMBD, Conjunto Mínimo Básico de Datos.](bmjopen2016013224f01){#BMJOPEN2016013224F1}

The principal characteristics of the study population are summarised in [table 1](#BMJOPEN2016013224TB1){ref-type="table"}. Mean age was 79.4±9.5 years, and most of the patients (52.6%) were women. CCI increased from 1.61 to 1.74 during the study period. Patients hospitalised with an ADR to anticoagulants had high frequency of medical conditions such as atrial fibrillation (AF; 63.16%), congestive heart failure (40.39%), chronic obstructive pulmonary disease (30.24%), diabetes and renal disease. The median length of stay fell from 8 (IQR=3) days in 2010 to 7 (IQR=2) days in 2013 (p=0.00). IHM varied little during the study period (from 10% in 2010 to 10.2% in 2013).

###### 

Baseline characteristics of ADRs to anticoagulants anticoagulant in Spain during the period 2010--2013

  ----------------------------------------------------------------------------------------------------------------------------------------
                                                   2010\          2011\          2012\          2013\          Total\           p Value
                                                   N (%)          N (%)          N (%)          N (%)          N (%)            
  ------------------------------------------------ -------------- -------------- -------------- -------------- ---------------- ----------
  Female                                           5509 (52.89)   6264 (52.41)   7287 (52.86)   7304 (52.58)   26 364 (52.68)   0.857

  Age, mean (SD)                                   78.92 (9.6)    79.24 (9.56)   79.66 (9.48)   79.81 (9.51)   79.45 (9.54)     \<0.0001

  Charlson comorbidity index, mean (SD)            1.61 (1.07)    1.64 (1.08)    1.68 (1.09)    1.74 (1.09)    1.67 (1.09)      \<0.0001

   Myocardial infarction                           547 (5.25)     610 (5.1)      649 (4.71)     580 (4.18)     2386 (4.77)      \<0.0001

   Congestive heart failure                        3987 (38.28)   4581 (38.33)   5697 (41.33)   5949 (42.83)   20 214 (40.39)   \<0.0001

   Peripheral vascular disease                     537 (5.16)     659 (5.51)     743 (5.39)     810 (5.83)     2749 (5.49)      0.131

   Cerebrovascular disease                         1225 (11.76)   1410 (11.8)    1546 (11.22)   1645 (11.84)   5826 (11.64)     0.332

   Dementia                                        478 (4.59)     560 (4.69)     686 (4.98)     666 (4.79)     2390 (4.78)      0.524

   Chronic pulmonary disease                       3070 (29.48)   3562 (29.81)   4181 (30.33)   4319 (31.09)   15 132 (30.24)   0.032

   Connective tissue disease---rheumatic disease   248 (2.38)     256 (2.14)     275 (1.99)     329 (2.37)     1108 (2.21)      0.102

   Peptic ulcer disease                            188 (1.81)     181 (1.51)     216 (1.57)     174 (1.25)     759 (1.52)       0.006

   Mild liver disease                              415 (3.98)     444 (3.72)     523 (3.79)     567 (4.08)     1949 (3.89)      0.403

   Diabetes without chronic complication           2650 (25.44)   3104 (25.97)   3512 (25.48)   3623 (26.08)   12 889 (25.76)   0.541

   Diabetes with chronic complication              290 (2.78)     327 (2.74)     423 (3.07)     450 (3.24)     1490 (2.98)      0.059

   Hemiplegia or paraplegia                        111 (1.07)     150 (1.26)     187 (1.36)     199 (1.43)     647 (1.29)       0.075

   Renal disease                                   2194 (21.07)   2672 (22.36)   3290 (23.87)   3552 (25.57)   11 708 (23.4)    \<0.0001

   Cancer                                          487 (4.68)     650 (5.44)     727 (5.27)     718 (5.17)     2582 (5.16)      0.064

   Moderate or severe liver disease                94 (0.9)       115 (0.96)     140 (1.02)     143 (1.03)     492 (0.98)       0.752

   Metastatic carcinoma                            260 (2.5)      316 (2.64)     333 (2.42)     365 (2.63)     1274 (2.55)      0.597

   AIDS/HIV                                        11 (0.11)      14 (0.12)      12 (0.09)      17 (0.12)      54 (0.11)        0.819

  Atrial fibrillation                              6441 (61.84)   7450 (62.34)   8792 (63.78)   8924 (64.24)   31 607 (63.16)   \<0.0001

  Thromboembolism                                  281 (2.7)      283 (2.37)     325 (2.36)     335 (2.41)     1224 (2.45)      0.308

  Hypertension                                     4156 (39.9)    4835 (40.46)   5618 (40.75)   5452 (39.25)   20 061 (40.09)   0.059

  Anaemia                                          3147 (30.22)   3513 (29.4)    4180 (30.32)   4107 (29.57)   14 947 (29.87)   0.279

  Surgery                                          689 (6.62)     748 (6.26)     774 (5.61)     818 (5.89)     3029 (6.05)      0.007

  Red cell transfusion                             2063 (19.81)   2339 (19.57)   2678 (19.43)   2360 (16.99)   9440 (18.86)     \<0.0001

  In-hospital mortality                            1042 (10)      1205 (10.08)   1491 (10.82)   1424 (10.25)   5162 (10.32)     0.134

  LOSH, median (IQR)                               8 (5--13)      7 (4--13)      7 (4--12)      7 (4--12)      8 (4--13)        \<0.0001
  ----------------------------------------------------------------------------------------------------------------------------------------

ADR, adverse drug reaction.

[Table 2](#BMJOPEN2016013224TB2){ref-type="table"} shows the annual hospital discharge rates for patients with an ADR to anticoagulants by sex and age group. The cumulative incidence of discharges increased from 22.3 cases per 100 000 inhabitants in 2010 to 29.8 cases per 100 000 inhabitants in 2013 (ie, a 24.9% increase). Cumulative incidence was significantly higher for men than women and in all age groups, although the main increases were observed in the older age groups (26.30% in patients aged ≥85 years; p\<0.05). The most frequent primary diagnoses and procedures most commonly associated with ADRs according to IHM are summarised in [table 3](#BMJOPEN2016013224TB3){ref-type="table"}. It is noteworthy that 20.6% of patients who died during their hospitalisation had a primary diagnosis of cardiovascular disease (ICD-9 codes 428, 402.91, 428.1, 404.91, 415.19, 428.9, 410.71, 411.1 and 428.23) and 16.8% had a primary diagnosis of bleeding (ICD-9 codes 729.92, 578.9, 578.1, 569.3, 431, 38.9, 599.71, 562.12, 599.7, 784.7, 786.3, 285.1 and 578), intracranial haemorrhage has been the most frequent diagnosis (5.23%), followed by blood vessel puncture (4.15%). The most frequent procedure administered during admission was blood transfusion (18.8%).

###### 

Incidence of ADRs to anticoagulants according to sex and age groups

                    2010     2011     2012     2013     Total    Relative change                                       
  ----------------- -------- -------- -------- -------- -------- ----------------- -------- -------- -------- -------- -------
  Male                                                                                                                 
   \<75 years\*     1441     6.72     1563     7.29     1694     7.92              1689     7.95     6387     7.47     15.47
   75--84 years     2368     190.52   2739     215.77   3124     243.30            3123     243.45   11 354   223.54   21.74
   ≥85 years\*      1097     331.61   1385     392.03   1680     452.69            1775     450.67   5937     409.71   26.42
   Total\*          4906     21.32    5687     24.65    6498     28.18             6587     28.72    23 678   25.72    25.77
  Female                                                                                                               
   \<75 years\*     1026     4.87     1127     5.34     1168     5.53              1224     5.81     4545     5.39     16.18
   75--84 year\*s   2582     146.53   2905     162.47   3363     186.85            3250     181.66   12 100   169.49   19.34
   ≥85 years\*      1901     265.79   2232     295.52   2756     351.54            2830     344.56   9719     315.98   25.04
   Total\*          5509     23.39    6264     26.47    7287     30.73             7304     30.87    26 364   27.87    24.23
  Total                                                                                                                
   \<75 years\*     2467     5.80     2690     6.32     2862     6.73              2913     6.89     10 932   6.43     15.82
   75--84 years\*   4950     164.72   5644     184.60   6487     210.35            6373     207.46   23 454   191.96   20.6
   ≥85 years\*      2998     286.60   3617     326.27   4436     384.04            4605     378.95   15 656   346.00   26.30
   Total\*          10 415   22.37    11 951   25.57    13 785   29.48             13 891   29.81    50 042   26.81    24.96

National Hospital Discharge Database (CMBD).

Cumulative incidence per 100 000 inhabitants. Cumulative incidence was calculated using the Spanish National Statistics Institute census projections.[@R22]

\*p\<0.05 (comparison by year: Poisson regression model for incidence rates, Pearson's χ^2^ for proportions).

ADR, adverse drug reaction; CMBD, Conjunto Mínimo Básico de Datos.

###### 

Most frequent primary diagnoses and procedures among ADRs to anticoagulants according to in-hospital mortality in Spain, 2010--2013

                                                                                                       Outcome                                 
  ---------------------------------------------------------------------------------------------------- --------- ------- ------ ------- ------ -------
  Cardiovascular disease (428, 402.91, 428.1, 404.91, 415.19, 428.9, 410.71, 411.1, 428.23)            8196      18.26   1068   20.69   9264   18.51
  Bleeding (729.92, 578.9, 578.1, 569.3, 431, 38.9, 599.71, 562.12, 599.7, 784.7, 786.3, 285.1, 578)   6530      14.55   870    16.85   7400   14.79
  Respiratory disease (519.8, 491.21, 518.81, 466, 518.84, 491.22, 494.1, 493.92)                      5764      12.84   490    9.49    6254   12.5
  Pneumonias (486, 507, 481)                                                                           3257      7.26    425    8.23    3682   7.36
  Renal disease (599, 584.9)                                                                           1868      4.16    237    4.59    2105   4.21
  Anaemia (280, 280.9, 285.9)                                                                          942       2.1     41     0.79    983    1.96
  Atrial fibrillation (427.31)                                                                         800       1.78    37     0.72    837    1.67
  Procedures                                                                                                                                   
   Surgery                                                                                             2657      5.92    372    7.21    3029   6.05
   Red cell transfusion                                                                                8416      18.75   1024   19.84   9440   18.86

National Hospital Discharge Database (CMBD).

ADR, adverse drug reaction; CMBD, Conjunto Mínimo Básico de Datos; ICD-9, International Classification of Diseases-Ninth Revision.

An adjusted multivariate analysis ([table 4](#BMJOPEN2016013224TB4){ref-type="table"}) revealed that IHM did not change significantly over time. We observed a statistically significant association between IHM and age, with the highest risk for the ≥85 age group (OR 2.67; 95% CI 2.44 to 2.93).

###### 

Multivariate analysis of the factors associated with IHM for all participants with ADRs to anticoagulants in Spain, from 2010 to 2013

                               OR (CI 95%)
  ---------------------------- ---------------------
  Age groups (years)           
   \<75                        1
   75--84                      1.65 (1.50 to 1.80)
   ≥85                         2.67 (2.44 to 2.93)
  Sex                          
   Male                        1
   Female                      0.99 (0.93 to 1.05)
  Charlson comorbidity index   1.21 (1.18 to 1.25)
  Red cell transfusion         
   No                          1
   Yes                         1.09 (1.01 to 1.17)
  Atrial fibrillation          
   No                          1
   Yes                         0.88 (0.83 to 0.94)
  Years                        
   2013                        1
   2012                        1.08 (0.99 to 1.06)
   2011                        1.01 (0.93 to 1.10)
   2010                        1.02 (0.94 to 1.11)

National Hospital Discharge Database (CMBD).

Calculated using logistic regression models: OR. The logistic regression multivariate models were built using 'death (yes/no)' as dependent variables.

ADR, adverse drug reaction; CMBD, Conjunto Mínimo Básico de Datos; IHM, in-hospital mortality.

A higher CCI was associated with a higher risk of death during admission (OR 1.21; 95% CI 1.18 to 1.25). Other factors associated with higher IHM were having a blood transfusion administered, whereas having AF (OR 0.88; 95% CI 0.83 to 0.94) as a diagnosis showed a protective effect.

Discussion {#s4}
==========

Oral anticoagulants are often associated with ADRs requiring admission to hospital.[@R15] [@R17] [@R25] Using data from the CMBD, we found that between 2010 and 2013, a total of 50 042 hospitalisations in Spain were with an ADR to anticoagulant drugs (ie, 6.38% of all hospitalisations with ADRs). This information is consistent with the 7.5% reported for anticoagulants in a study covering the period 2001--2006 to estimate the burden of ADR-related hospitalisations in Spain.[@R9] The values we report are lower than those found in the 5-year study performed by Ruiter *et al*[@R2] in the Netherlands, in which 23% of ADR-related hospital admissions in individuals aged ≥55 years were associated with anticoagulants. Our results are also lower than the 18.3% frequency of adverse reactions to anticoagulants reported in a recent German study on the impact of ADR-related admissions to internal medicine departments, although the study period was shorter than ours.[@R26] The results of our study show an increase in the incidence of ADR-related hospitalisations during the study period, irrespective of whether the numerator is the general population, the number of hospital admissions or the number of prescriptions of anticoagulants. All three options are suitable for a qualitative analysis to identify the age groups at greatest risk. In addition, the high proportion of elderly patients, with more frequent comorbidity and polypharmacy, is consistent with data from other studies.[@R7] [@R14]

Female sex is a recognised risk factor for adverse reactions to specific groups of drugs.[@R2] [@R7] [@R27] [@R28] If we focus on the safety profile of anticoagulant drugs, we find that the potential sex differences in the onset of adverse reactions have also been analysed in several meta-analyses, with varying results.[@R29] However, in our study, sex as a risk factor behaved differently. During the 4-year study period, we observed an increase in the incidence of anticoagulant-related hospitalisations, which was greater in men than in women for all age groups. These data are consistent with those reported by Rodenburg *et al*,[@R32] whose objective was to identify possible differences in ADRs to cardiovascular drugs between men and women over a 6-year period. The authors found that admissions for ADRs to anticoagulants and salicylates were more common in men (RR 0.94; 95% CI 0.90 to 0.98). In recent years, it has become clear that women and men differ in their response to anticoagulant drugs, as shown in the study by Blanco-Molina *et al*[@R33] in Spain, in which analysis of a sample of 47 499 patients with venous thromboembolism showed that the outcome of therapy with anticoagulants could vary depending on the sex of the patient. Similarly, a recent study in primary care performed by Precioso Costa *et al*[@R34] to determine the degree of control and adherence to therapy in a sample of patients treated with acenocoumarol found that poor control of the international normalised ratio was more common among men (2.77±0.11) than among women (2.66±0.08; p\<0.05).

Our analysis of the CMBD registers showed that most patients hospitalised for ADRs to anticoagulants were elderly persons aged 79.45±9.54 years with various clinical conditions such as congestive heart failure and AF, which increase the vulnerability of this group to anticoagulant-induced ADRs. Our results show that the severity of the underlying disease, as expressed by the CCI (1.67±1.09), was high in patients admitted to hospital with anticoagulant-induced reactions; this finding is consistent with those of the study of Alexopoulou *et al*[@R35] in Greece, where patients who had been hospitalised for ADRs had more comorbid conditions (CCI 1.7) than patients admitted for other reasons. Nevertheless, we must not forget that having multiple comorbidities is associated with polypharmacy,[@R12] as described in a recent study performed in France by Olivier *et al*[@R11] in patients aged ≥65 years and in whom the number of drugs taken was a risk factor for ADR-associated hospitalisations (OR 1.18; 95% CI 1.08 to 1.29).

Oral anticoagulants are the most effective therapy for the prevention of ischaemic stroke and systemic embolism related to AF. During the previous decade, the number of patients who received treatment with oral anticoagulants has increased, mainly owing to the higher number of elderly patients with AF,[@R36] [@R37] for whom this therapy is indicated in order to prevent cerebrovascular accidents.[@R38] Analysis of primary diagnoses associated with ADRs to anticoagulants among hospitalised patients reveals that the primary diagnosis was cardiovascular disease in 18.5% of cases and AF in 1.67% of cases, thus potentially explaining why these patients were receiving treatment with anticoagulants. Other diagnoses, such as bleeding (14.79%) and blood transfusion (18.86%) could indicate the reason why patients were hospitalised or what happened during hospitalisation. Finally, although not associated with anticoagulant drugs, primary diagnoses such as renal insufficiency (4.21%) could be considered a risk factor if the patient\'s consumption of anticoagulants is high.

With respect to bleeding as the main diagnosis, our results are consistent with those of studies that associate this diagnosis as the main adverse reaction to anticoagulants. Piazza *et al*[@R15] performed a 5-year retrospective study to determine the clinical characteristics, types and outcomes of adverse events associated with anticoagulant drugs and found that 25% of adverse reactions comprised bleeding events and that 17% required transfusion of at least one unit of packed red blood cells. However, it is important to remember that the predictors of bleeding in patients undergoing treatment with anticoagulants are mainly clinical factors that include uncontrolled hypertension, a history of myocardial infarction or ischaemic heart disease, cerebrovascular disease, anaemia or a history of bleeding, and concomitant use of other drugs such as antiplatelet agents.[@R39]

Patients admitted for adverse reactions to anticoagulants often die, usually because of the profile of patients taking these drugs (eg, old age, comorbidity and polypharmacy).[@R40] We found that the IHM associated with adverse reactions to anticoagulants remained constant throughout the study period, with values close to 10%, which were higher than the 6.9% reported by Heng *et al*[@R25] based on the data from the French Database Programme de Médicalisation des Systèmes d\'Information (PMSI), including patients aged \>75 years.

In contrast with results from other studies, where fatal ADRs seem mainly to affect women,[@R12] IHM did not seem to be affected by sex in our study.

Our multivariate analysis showed that individuals aged ≥85 years who were admitted to hospital with adverse reactions to anticoagulants are twice as likely to die as those aged \<75 years (OR 2.67; 95% CI 2.44 to 2.93). Similarly, the CCI acts as a predictor of IHM in this age group, since comorbidity worsens the patient\'s clinical status in the case of an adverse reaction to anticoagulants. In this context, it is noteworthy that AF, the most common significant cardiac arrhythmia, is associated with substantial morbidity from stroke and thromboembolism. According to data from the OFRECE study, which analysed the prevalence of AF in Spain, the prevalence of AF in patients aged \>80 years is high (17.7%).[@R37] AF is also associated with increased mortality,[@R41] although our data analysis revealed that a diagnosis of AF is not a risk factor for IHM in patients admitted for adverse reactions to anticoagulants (OR 0.88; 95% CI 0.83 to 0.94). We have analysed three groups: patients without AF, patients with AF as comorbidity and patients with AF as the primary diagnosis. It can be observed that IHM values are similar between patients without AF and patients presenting AF as a comorbidity (10.5% vs 10.4%). Patients with AF as a primary diagnosis have much lower IHM (∼4.4% vs 10%) Patients with AF as the first diagnosis are more frequently women (65.7% vs 47.9% and 55.2% among those without AF and with AF as a comorbidity, respectively), with a mean age between the other two group (78.7 vs 76.8 years among those without AF and 81.1 years among those with AF as a comorbid condition) and with a mean Charlson index lower than the other groups two groups (1.5 vs 1.63 and 1.7).

This finding could be associated with the type of treatment of the disease in this patient group. VKA have long been the only available oral anticoagulant for prevention of the thromboembolic complications of AF. These drugs are clearly efficacious, with a relative reduction in the risk of ischaemic stroke in elderly patients. However, the clinical challenge of these drugs is to reach an optimal degree of protection under strict supervision owing to their narrow therapeutic margin, interactions with other drugs and the need for strict control of the degree of anticoagulation. Many patients on treatment with VKA spend time outside of the therapeutic range. Some recently published studies in Spain stress on the high percentage of patients who are not well controlled with VKAs. These values range from 41.5% to 43.7%, according to the results of the CALIFA study,[@R42] and the ANFAGAL study[@R43] the prevalence of poorly controlled VKA anticoagulation in Spain in patients with non-valvular AF.

Newly developed anticoagulant agents, such as the direct thrombin inhibitor dabigatran etexilate and the direct factor X inhibitors rivaroxaban and apixaban and edoxaban were recently shown to have a favourable risk--benefit ratio under various clinical conditions where anticoagulants are indicated, as is the case with AF.[@R44] The meta-analysis conducted by Ruff *et al*[@R45] to assess the relative benefit of new oral anticoagulants in randomised trials in patients with AF, showed that the new oral anticoagulants also significantly reduce all-cause mortality (0.90, 0.85 to 0.95; p=0.0003).

Strengths and limitations {#s4a}
-------------------------

Our study has both strengths and limitations. The main strength lies in the large sample size and standardised methodology, which was maintained throughout the study period and has previously been used to investigate ADR-related hospital admissions in Spain and elsewhere.[@R9] [@R16] [@R26] We believe that the length of the study period and the exhaustive data provided by the CMBD provide sufficient internal validity, which, in quantitative terms, is seen in the constant frequency of episodes detected every year and, in qualitative terms, in the identification of the age groups at the greatest risk.

Nevertheless, our study is subject to limitations. Given that our findings are based on the diagnosis at discharge, the cumulative incidence of ADRs to anticoagulants among hospitalised patients is probably substantially underestimated. Another limitation is the possibility that ADR-related hospitalisations also include cases in which the ADR occurred during admission, although in our opinion, the possibility that an adverse reaction to an anticoagulant during admission is coded as the main diagnosis seems very low. Furthermore, as a consequence of the study design, we were not able to verify whether the patient was already taking an anticoagulant or whether the reaction resulted from taking an anticoagulant during admission. The Spanish National Hospital Discharge Database (CMBD), includes no data regarding patient treatments or drug consumption. Spanish CMBD does not include data regarding the time of start of treatment with anticoagulants before the adverse reaction appeared. Consequently, it has not been possible for us to include any data in the polymedication analysis that would allow us to assess drug interactions with anticoagulants. In addition, we were unable to specify which specific anticoagulant or type of anticoagulant the patient took. We were unable to identify in detail the specific pharmacological classes involved in ADRs to anticoagulants among hospitalised patients.

Conclusions {#s5}
===========

In conclusion, during the study period, 50 042 individuals were hospitalised in Spain for adverse reactions to anticoagulants.

Cumulative incidence increased during this time and was significantly higher for men than women and in all age groups. Older patients were particularly susceptible to being hospitalised with an adverse reaction to an anticoagulant. Our results strongly suggest that individuals \>75 years of age with a high CCI had a higher risk of death during admission.

Oral anticoagulant therapy is complex due to the need for control and the haemorrhagic risk the therapy entails The use of anticoagulants requires custom management and proper selection of treatments, since many of these patients have multiple comorbidities and polypharmacy and some anticoagulants have a high percentage of drug interactions.
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